Skip to content

Study · Randomized controlled trial · n = 22 · 1998

11 results

Randomised controlled trial of recombinant human growth hormone in prepubertal and pubertal renal transplant recipients. British Association for Pediatric Nephrology.

Maxwell H, Rees L

Archives of disease in childhood1 Dec 1998Cited by 53 (Europe PMC)

PMID10210991 (opens in a new tab)PMCIDPMC1717762 (opens in a new tab)DOI10.1136/adc.79.6.481 (opens in a new tab)PepBankPUB-10210991
Source linkPubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

  1. 01HumanRandomized controlled trialSafety outcome

    In renal transplant children, GFR change did not differ significantly: rhGH 9.9 (5.4) versus controls -1.6 (7.6) ml/min/1.73 m2, mean (SE).

    In plain wordsIn renal transplant children, kidney filtration changes did not differ significantly between rhGH and controls.

    Peptide
    HGH (somatotropin)
    Outcome
    No significant changeGFR change
    Study

    n = 22

    Comparator
    Controls
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · first yearAs given in this study (human).

    Measurements

    GFR change mean
    9.9 ml/min/1.73 m2
    rhGH treated group
    GFR change SE
    5.4 ml/min/1.73 m2
    rhGH treated group
    GFR change mean
    −1.6 ml/min/1.73 m2
    control group
    GFR change SE
    7.6 ml/min/1.73 m2
    control group

    Source sentences

    Summary
    Comparing all treated and control children, there was no significant change in GFR: treated group, mean (SE) 9.9 (5.4) ml/min/1.73 m2 v control group, -1.6 (7.6) ml/min/1.73 m2.
    3 context sentences
    Summary · context
    A two year randomised controlled trial.
    Summary · context
    Fifteen prepubertal and seven pubertal children: mean (SD) age, 13.0 (2.6) and 15.2 (2.4) years, respectively; mean (SD) GFR, 51 (30) and 48 (17) ml/min/1.73 m2, respectively.
    Summary · context
    Six prepubertal and three pubertal children were controls during the first year; all received rhGH in the second year.
  2. 02HumanRandomized controlled trialSafety outcome

    In renal transplant children, rejection incidence did not differ: eight episodes in 13 rhGH recipients versus five in nine controls.

    In plain wordsIn renal transplant children, rejection incidence did not differ between rhGH recipients and controls.

    Peptide
    HGH (somatotropin)
    Outcome
    No significant changeRejection episodes
    Study

    n = 22

    Comparator
    Controls
    Outcome group
    Adverse events · Kidney and urinary
    Studied dose
    Dose not stated · first yearAs given in this study (human).

    Measurements

    Rejection episodes
    8 episodes
    rhGH group, first year
    Patients
    13 patients
    rhGH group
    Rejection episodes
    5 episodes
    control group, first year
    Patients
    9 patients
    control group

    Source sentences

    Summary
    There were also no differences in the incidence of rejection in the first year: eight episodes in 13 patients v five episodes in nine patients, respectively.
    3 context sentences
    Summary · context
    A two year randomised controlled trial.
    Summary · context
    Fifteen prepubertal and seven pubertal children: mean (SD) age, 13.0 (2.6) and 15.2 (2.4) years, respectively; mean (SD) GFR, 51 (30) and 48 (17) ml/min/1.73 m2, respectively.
    Summary · context
    Six prepubertal and three pubertal children were controls during the first year; all received rhGH in the second year.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In prepubertal renal transplant recipients, rhGH increased height velocity versus controls: 8.1 (0.9) versus 3.7 (0.6) cm/year, mean (SE).

    In plain wordsIn prepubertal renal transplant recipients, height velocity was greater with rhGH than in controls.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreasePrepubertal height velocity
    Study

    n = 15

    Comparator
    Controls
    Outcome group
    Linear growth · Endocrine and hormones
    Studied dose
    Dose not stated · first yearAs given in this study (human).

    Measurements

    Height velocity mean
    8.1 cm/year
    rhGH treated group
    Height velocity SE
    0.9 cm/year
    rhGH treated group
    Height velocity mean
    3.7 cm/year
    control group
    Height velocity SE
    0.6 cm/year
    control group

    Source sentences

    Summary
    In the first year, mean (SE) HV and delta HSDS in the prepubertal treated group increased compared with controls: 8.1 (0.9) v 3.7 (0.6) cm/year and 0.6 (0.1) v -0.3 (0.2), respectively.
    3 context sentences
    Summary · context
    A two year randomised controlled trial.
    Summary · context
    Fifteen prepubertal and seven pubertal children: mean (SD) age, 13.0 (2.6) and 15.2 (2.4) years, respectively; mean (SD) GFR, 51 (30) and 48 (17) ml/min/1.73 m2, respectively.
    Summary · context
    Six prepubertal and three pubertal children were controls during the first year; all received rhGH in the second year.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In prepubertal renal transplant recipients, height SDS increased more with rhGH than controls: 0.6 (0.1) versus -0.3 (0.2), mean (SE).

    In plain wordsIn prepubertal renal transplant recipients, height scores increased more with rhGH than in controls.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreasePrepubertal height SDS change
    Study

    n = 15

    Comparator
    Controls
    Outcome group
    Linear growth · Endocrine and hormones
    Studied dose
    Dose not stated · first yearAs given in this study (human).

    Measurements

    Change in height SDS mean
    0.6 SDS
    rhGH treated group
    Change in height SDS SE
    0.1 SDS
    rhGH treated group
    Change in height SDS mean
    −0.3 SDS
    control group
    Change in height SDS SE
    0.2 SDS
    control group

    Source sentences

    Summary
    In the first year, mean (SE) HV and delta HSDS in the prepubertal treated group increased compared with controls: 8.1 (0.9) v 3.7 (0.6) cm/year and 0.6 (0.1) v -0.3 (0.2), respectively.
    3 context sentences
    Summary · context
    A two year randomised controlled trial.
    Summary · context
    Fifteen prepubertal and seven pubertal children: mean (SD) age, 13.0 (2.6) and 15.2 (2.4) years, respectively; mean (SD) GFR, 51 (30) and 48 (17) ml/min/1.73 m2, respectively.
    Summary · context
    Six prepubertal and three pubertal children were controls during the first year; all received rhGH in the second year.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In pubertal renal transplant recipients, rhGH increased height velocity versus controls: 10.1 (0.6) versus 3.9 (1.3) cm/year, mean (SE).

    In plain wordsIn pubertal renal transplant recipients, height velocity was greater with rhGH than in controls.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreasePubertal height velocity
    Study

    n = 7

    Comparator
    Controls
    Outcome group
    Linear growth · Endocrine and hormones
    Studied dose
    Dose not stated · first yearAs given in this study (human).

    Measurements

    Height velocity mean
    10.1 cm/year
    rhGH treated group
    Height velocity SE
    0.6 cm/year
    rhGH treated group
    Height velocity mean
    3.9 cm/year
    control group
    Height velocity SE
    1.3 cm/year
    control group

    Source sentences

    Summary
    In the pubertal treated group, mean (SE) HV and delta HSDS were also greater: 10.1 (0.6) v 3.9 (1.3) cm/year and 0.6 (0.1) v -0.1 (0.2), respectively.
    3 context sentences
    Summary · context
    A two year randomised controlled trial.
    Summary · context
    Fifteen prepubertal and seven pubertal children: mean (SD) age, 13.0 (2.6) and 15.2 (2.4) years, respectively; mean (SD) GFR, 51 (30) and 48 (17) ml/min/1.73 m2, respectively.
    Summary · context
    Six prepubertal and three pubertal children were controls during the first year; all received rhGH in the second year.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In pubertal renal transplant recipients, height SDS increased more with rhGH than controls: 0.6 (0.1) versus -0.1 (0.2), mean (SE).

    In plain wordsIn pubertal renal transplant recipients, height scores increased more with rhGH than in controls.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreasePubertal height SDS change
    Study

    n = 7

    Comparator
    Controls
    Outcome group
    Linear growth · Endocrine and hormones
    Studied dose
    Dose not stated · first yearAs given in this study (human).

    Measurements

    Change in height SDS mean
    0.6 SDS
    rhGH treated group
    Change in height SDS SE
    0.1 SDS
    rhGH treated group
    Change in height SDS mean
    −0.1 SDS
    control group
    Change in height SDS SE
    0.2 SDS
    control group

    Source sentences

    Summary
    In the pubertal treated group, mean (SE) HV and delta HSDS were also greater: 10.1 (0.6) v 3.9 (1.3) cm/year and 0.6 (0.1) v -0.1 (0.2), respectively.
    3 context sentences
    Summary · context
    A two year randomised controlled trial.
    Summary · context
    Fifteen prepubertal and seven pubertal children: mean (SD) age, 13.0 (2.6) and 15.2 (2.4) years, respectively; mean (SD) GFR, 51 (30) and 48 (17) ml/min/1.73 m2, respectively.
    Summary · context
    Six prepubertal and three pubertal children were controls during the first year; all received rhGH in the second year.
  7. 07HumanNon-randomized trialSafety outcome

    In renal transplant children, phosphate rose during the first year of rhGH treatment, but not thereafter.

    In plain wordsIn renal transplant children, phosphate increased during the first year of rhGH treatment, but not thereafter.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreasePhosphate concentration
    Study

    n: not reported in source

    Comparator
    Pretreatment
    Outcome group
    Electrolyte balance · Endocrine and hormones
    Studied dose
    Dose not stated · first yearAs given in this study (human).

    Source sentences

    Summary
    Phosphate, alkaline phosphatase (ALP), parathyroid hormone (PTH), and fasting insulin concentrations rose during the first year of treatment, but not thereafter.
    3 context sentences
    Summary · context
    A two year randomised controlled trial.
    Summary · context
    Fifteen prepubertal and seven pubertal children: mean (SD) age, 13.0 (2.6) and 15.2 (2.4) years, respectively; mean (SD) GFR, 51 (30) and 48 (17) ml/min/1.73 m2, respectively.
    Summary · context
    Six prepubertal and three pubertal children were controls during the first year; all received rhGH in the second year.
  8. 08HumanNon-randomized trialSafety outcome

    In renal transplant children, alkaline phosphatase rose during the first year of rhGH treatment, but not thereafter.

    In plain wordsIn renal transplant children, alkaline phosphatase increased during the first year of rhGH treatment, but not thereafter.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseAlkaline phosphatase concentration
    Study

    n: not reported in source

    Comparator
    Pretreatment
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · first yearAs given in this study (human).

    Source sentences

    Summary
    Phosphate, alkaline phosphatase (ALP), parathyroid hormone (PTH), and fasting insulin concentrations rose during the first year of treatment, but not thereafter.
    3 context sentences
    Summary · context
    A two year randomised controlled trial.
    Summary · context
    Fifteen prepubertal and seven pubertal children: mean (SD) age, 13.0 (2.6) and 15.2 (2.4) years, respectively; mean (SD) GFR, 51 (30) and 48 (17) ml/min/1.73 m2, respectively.
    Summary · context
    Six prepubertal and three pubertal children were controls during the first year; all received rhGH in the second year.
  9. 09HumanNon-randomized trialSafety outcome

    In renal transplant children, parathyroid hormone rose during the first year of rhGH treatment, but not thereafter.

    In plain wordsIn renal transplant children, parathyroid hormone increased during the first year of rhGH treatment, but not thereafter.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseParathyroid hormone concentration
    Study

    n: not reported in source

    Comparator
    Pretreatment
    Outcome group
    Electrolyte balance · Endocrine and hormones
    Studied dose
    Dose not stated · first yearAs given in this study (human).

    Source sentences

    Summary
    Phosphate, alkaline phosphatase (ALP), parathyroid hormone (PTH), and fasting insulin concentrations rose during the first year of treatment, but not thereafter.
    3 context sentences
    Summary · context
    A two year randomised controlled trial.
    Summary · context
    Fifteen prepubertal and seven pubertal children: mean (SD) age, 13.0 (2.6) and 15.2 (2.4) years, respectively; mean (SD) GFR, 51 (30) and 48 (17) ml/min/1.73 m2, respectively.
    Summary · context
    Six prepubertal and three pubertal children were controls during the first year; all received rhGH in the second year.
  10. 10HumanNon-randomized trialSafety outcome

    In renal transplant children, fasting insulin rose during the first year of rhGH treatment, but not thereafter.

    In plain wordsIn renal transplant children, fasting insulin increased during the first year of rhGH treatment, but not thereafter.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseFasting insulin concentration
    Study

    n: not reported in source

    Comparator
    Pretreatment
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · first yearAs given in this study (human).

    Source sentences

    Summary
    Phosphate, alkaline phosphatase (ALP), parathyroid hormone (PTH), and fasting insulin concentrations rose during the first year of treatment, but not thereafter.
    3 context sentences
    Summary · context
    A two year randomised controlled trial.
    Summary · context
    Fifteen prepubertal and seven pubertal children: mean (SD) age, 13.0 (2.6) and 15.2 (2.4) years, respectively; mean (SD) GFR, 51 (30) and 48 (17) ml/min/1.73 m2, respectively.
    Summary · context
    Six prepubertal and three pubertal children were controls during the first year; all received rhGH in the second year.
  11. 11HumanNon-randomized trialEfficacy outcome

    In renal transplant children, height velocity remained above baseline during the second year of rhGH treatment.

    In plain wordsIn renal transplant children, height velocity remained above baseline during the second year of rhGH treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseSecond-year height velocity
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Linear growth · Endocrine and hormones
    Studied dose
    Dose not stated · second year of treatmentAs given in this study (human).

    Source sentences

    Summary
    In the second year of treatment, HV remained above baseline.
    3 context sentences
    Summary · context
    A two year randomised controlled trial.
    Summary · context
    Fifteen prepubertal and seven pubertal children: mean (SD) age, 13.0 (2.6) and 15.2 (2.4) years, respectively; mean (SD) GFR, 51 (30) and 48 (17) ml/min/1.73 m2, respectively.
    Summary · context
    Six prepubertal and three pubertal children were controls during the first year; all received rhGH in the second year.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.